232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 232,697 shares of the biopharmaceutical company's stock, valued at approximately $13,408,000.

A number of other institutional investors have also recently modified their holdings of BMY. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $27,000. Bayban acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $32,000. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company's stock.

Analysts Set New Price Targets

BMY has been the subject of several research analyst reports. Citigroup reiterated a "neutral" rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 27th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. TD Cowen initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating on the stock. Finally, Guggenheim reaffirmed a "buy" rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $66.06.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $66.62 on Friday. The business has a 50-day moving average price of $61.76 and a two-hundred day moving average price of $59.68. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company has a market cap of $136.09 billion, a P/E ratio of 14.67, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm's revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb's dividend payout ratio is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source